Joseph A Kovacs

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4881269/publications.pdf

Version: 2024-02-01

272 papers

21,327 citations

72 h-index

10351

136 g-index

277 all docs

277 docs citations

times ranked

277

11309 citing authors

#	Article	IF	CITATIONS
1	Genetic and Epidemiologic Analyses of an Outbreak of <i>Pneumocystis jirovecii</i> Pneumonia Among Kidney Transplant Recipients in the United States. Clinical Infectious Diseases, 2022, 74, 639-647.	2.9	9
2	Mucosal-Associated Invariant T Cells Accumulate in the Lungs during Murine Pneumocystis Infection but Are Not Required for Clearance. Journal of Fungi (Basel, Switzerland), 2022, 8, 645.	1.5	0
3	Genomic insights into the host specific adaptation of the Pneumocystis genus. Communications Biology, 2021, 4, 305.	2.0	23
4	Advances toward Curing HIV-1 Infection in Tissue Reservoirs. Journal of Virology, 2020, 94, .	1.5	53
5	A Novel Encochleated Formulation Improves Atovaquone Activity in a Murine Model of Pneumocystis Pneumonia. Journal of Infectious Diseases, 2020, 224, 326-331.	1.9	О
6	MUC1 mediates < scp > <i>Pneumocystis murina </i> binding to airway epithelial cells. Cellular Microbiology, 2020, 22, e13182.	1.1	7
7	Humans Are Selectively Exposed to Pneumocystis jirovecii. MBio, 2020, 11, .	1.8	8
8	Diversity and Complexity of the Large Surface Protein Family in the Compacted Genomes of Multiple <i>Pneumocystis</i> Species. MBio, 2020, 11, .	1.8	11
9	Characterization of Pneumocystis murina Bgl2, an Endo- \hat{l}^2 -1,3-Glucanase and Glucanosyltransferase. Journal of Infectious Diseases, 2019, 220, 657-665.	1.9	2
10	Adoptive lymphocyte transfer to an HIV-infected progressor from an elite controller. JCI Insight, 2019, 4, .	2.3	6
11	Characterization of p57, a Stage-Specific Antigen of Pneumocystis murina. Journal of Infectious Diseases, 2018, 218, 282-290.	1.9	11
12	Cytokine-Mediated Systemic Adverse Drug Reactions in a Drug–Drug Interaction Study of Dolutegravir With Once-Weekly Isoniazid and Rifapentine. Clinical Infectious Diseases, 2018, 67, 193-201.	2.9	49
13	Inability to Culture Pneumocystis jirovecii. MBio, 2018, 9, .	1.8	20
14	Genetic diversity of <i>Pneumocystis jirovecii</i> from a cluster of cases of pneumonia in renal transplant patients: Crossâ€sectional study. Mycoses, 2018, 61, 845-852.	1.8	9
15	Comparative Population Genomics Analysis of the Mammalian Fungal Pathogen <i>Pneumocystis</i> MBio, 2018, 9, .	1.8	23
16	The Major Surface Glycoprotein of Pneumocystis murina Does Not Activate Dendritic Cells. Journal of Infectious Diseases, 2018, 218, 1631-1640.	1.9	12
17	A Molecular Window into the Biology and Epidemiology of Pneumocystis spp. Clinical Microbiology Reviews, 2018, 31, .	5.7	58
18	Pneumocystis: A Polysaccharide Anomaly. FASEB Journal, 2018, 32, 818.8.	0.2	0

#	Article	IF	CITATIONS
19	<i>Pneumocystis</i> Colonization in Asthmatic Patients not Receiving Oral Corticosteroid Therapy. Journal of Investigative Medicine, 2017, 65, 800-802.	0.7	5
20	Pulmonary Interleukin-17-Positive Lymphocytes Increase during Pneumocystis murina Infection but Are Not Required for Clearance of Pneumocystis. Infection and Immunity, 2017, 85, .	1.0	12
21	T-cell Activation and E-selectin Are Associated With Coronary Plaque in HIV-infected Young Adults. Pediatric Infectious Disease Journal, 2017, 36, 63-65.	1.1	6
22	Adverse effects of antiretroviral therapy on liver hepatocytes and endothelium in HIV patients: An ultrastructural perspective. Ultrastructural Pathology, 2017, 41, 186-195.	0.4	20
23	Magnetic Resonance Elastography Shear Wave Velocity Correlates with Liver Fibrosis and Hepatic Venous Pressure Gradient in Adults with Advanced Liver Disease. BioMed Research International, 2017, 2017, 1-8.	0.9	29
24	Drug Resistance in Pneumocystis jirovecii. , 2017, , 1147-1162.		0
25	Simtuzumab treatment of advanced liver fibrosis in <scp>HIV</scp> and <scp>HCV</scp> â€infected adults: results of a 6â€month openâ€label safety trial. Liver International, 2016, 36, 1783-1792.	1.9	79
26	Distinguishing highly similar gene isoforms with a clustering-based bioinformatics analysis of PacBio single-molecule long reads. BioData Mining, 2016, 9, 13.	2.2	20
27	Genome analysis of three Pneumocystis species reveals adaptation mechanisms to life exclusively in mammalian hosts. Nature Communications, 2016, 7, 10740.	5.8	153
28	î²-Glucans Are Masked but Contribute to Pulmonary Inflammation During <i>Pneumocystis</i> Pneumonia. Journal of Infectious Diseases, 2016, 214, 782-791.	1.9	35
29	Efavirenz but Not Atazanavir/Ritonavir Significantly Reduces Atovaquone Concentrations in HIV-Infected Subjects. Clinical Infectious Diseases, 2016, 62, 1036-1042.	2.9	9
30	Pneumocystis jirovecii Pneumonia in Human Immunodeficiency Virus Infection. Seminars in Respiratory and Critical Care Medicine, 2016, 37, 243-256.	0.8	24
31	Lack of an Effect of Ritonavir Alone and Lopinavir-Ritonavir on the Pharmacokinetics of Fenofibric Acid in Healthy Volunteers. Pharmacotherapy, 2016, 36, 49-56.	1.2	10
32	Clonally expanded CD4 ⁺ T cells can produce infectious HIV-1 in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 1883-1888.	3.3	302
33	Serological diagnosis of pulmonary Mycobacterium tuberculosis infection by LIPS using a multiple antigen mixture. BMC Microbiology, 2015, 15, 205.	1.3	18
34	Transient elastography for the detection of hepatic fibrosis in HIV-monoinfected adults with elevated aminotransferases on antiretroviral therapy. Aids, 2015, 29, 2297-2302.	1.0	42
35	Lack of Evidence for Molecular Mimicry in HIV-Infected Subjects. PLoS ONE, 2015, 10, e0127662.	1.1	1
36	Characterization of chemokine and chemokine receptor expression during Pneumocystis infection in healthy and immunodeficient mice. Microbes and Infection, 2015, 17, 638-650.	1.0	7

#	Article	IF	Citations
37	Pioglitazone for Hepatic Steatosis in HIV/Hepatitis C Virus Coinfection. AIDS Research and Human Retroviruses, 2015, 31, 961-966.	0.5	15
38	Pneumocystis Encodes a Functional Endo- \hat{l}^2 -1,3-glucanase That is Expressed Exclusively in Cysts. Journal of Infectious Diseases, 2015, 211, 719-728.	1.9	17
39	Nonalcoholic Steatohepatitis and Hepatic Fibrosis in HIV-1-Monoinfected Adults With Elevated Aminotransferase Levels on Antiretroviral Therapy. Clinical Infectious Diseases, 2015, 60, 1569-78.	2.9	81
40	Influence of Panax ginsengon the Steady State Pharmacokinetic Profile of Lopinavir-Ritonavir in Healthy Volunteers. Pharmacotherapy, 2014, 34, 1151-1158.	1.2	13
41	Mutational Analysis of Pneumocystis jirovecii Dihydropteroate Synthase and Dihydrofolate Reductase Genes in HIV-Infected Patients in China. Journal of Clinical Microbiology, 2014, 52, 4017-4019.	1.8	10
42	CXCR4/IgG-expressing plasma cells are associated with human gastrointestinal tissue inflammation. Journal of Allergy and Clinical Immunology, 2014, 133, 1676-1685.e5.	1.5	20
43	HIV Antibody Characterization as a Method to Quantify Reservoir Size During Curative Interventions. Journal of Infectious Diseases, 2014, 209, 1613-1617.	1.9	48
44	Clearance of Pneumocystis murina infection is not dependent on MyD88. Microbes and Infection, 2014, 16, 522-527.	1.0	3
45	11 Molecular Epidemiology of Pneumocystis Outbreaks. , 2014, , 191-203.		0
46	Quantitative determinations of anti-Kaposi sarcoma–associated herpesvirus antibody levels in men who have sex with men. Diagnostic Microbiology and Infectious Disease, 2013, 76, 56-60.	0.8	6
47	Sequencing and characterization of the complete mitochondrial genomes of three Pneumocystis species provide new insights into divergence between human and rodent Pneumocystis. FASEB Journal, 2013, 27, 1962-1972.	0.2	40
48	Influence of Low-Dose Ritonavir With and Without Darunavir on the Pharmacokinetics and Pharmacodynamics of Inhaled Beclomethasone. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 63, 355-361.	0.9	32
49	Expression of Pneumocystis jirovecii Major Surface Glycoprotein in Saccharomyces cerevisiae. Journal of Infectious Diseases, 2013, 208, 170-179.	1.9	10
50	Fatigue-Related Gene Networks Identified in CD14 ⁺ Cells Isolated From HIV-Infected Patientsâ€"Part II. Biological Research for Nursing, 2013, 15, 152-159.	1.0	2
51	Reply to Hauser et al. Clinical Infectious Diseases, 2013, 56, 166-167.	2.9	1
52	Characterization of Pneumocystis Major Surface Glycoprotein Gene (<i>msg</i>) Promoter Activity in Saccharomyces cerevisiae. Eukaryotic Cell, 2013, 12, 1349-1355.	3.4	8
53	A Benchmark Study on Error Assessment and Quality Control of CCS Reads Derived from the PacBio RS. Journal of Data Mining in Genomics & Proteomics, 2013, 04, .	0.5	57
54	HIV Populations Are Large and Accumulate High Genetic Diversity in a Nonlinear Fashion. Journal of Virology, 2013, 87, 10313-10323.	1.5	109

#	Article	IF	CITATIONS
55	Fatigue-Related Gene Networks Identified in CD14+ Cells Isolated From HIV-Infected Patientsâ€"Part I. Biological Research for Nursing, 2013, 15, 137-151.	1.0	8
56	Elevations in D-dimer and C-reactive protein are associated with the development of osteonecrosis of the hip in HIV-infected adults. Aids, 2013, 27, 591-595.	1.0	17
57	Outbreak of Pneumocystis Pneumonia in Renal and Liver Transplant Patients Caused by Genotypically Distinct Strains of Pneumocystis jirovecii. Transplantation, 2013, 96, 834-842.	0.5	57
58	Altered Antibody Profiles against Common Infectious Agents in Chronic Disease. PLoS ONE, 2013, 8, e81635.	1.1	10
59	The Cancer-Associated Virus Landscape in HIV Patients with Oral Hairy Leukoplakia, Kaposi's Sarcoma, and Non-Hodgkin Lymphoma. AIDS Research and Treatment, 2012, 2012, 1-10.	0.3	5
60	Outbreaks of Pneumocystis Pneumonia in 2 Renal Transplant Centers Linked to a Single Strain of Pneumocystis: Implications for Transmission and Virulence. Clinical Infectious Diseases, 2012, 54, 1437-1444.	2.9	67
61	Reclassification of risk of death with the knowledge of D-dimer in a cohort of treated HIV-infected individuals. Aids, 2012, 26, 1707-1717.	1.0	8
62	Comprehensive analysis of unique cases with extraordinary control over HIV replication. Blood, 2012, 119, 4645-4655.	0.6	86
63	Discordant antibody and cellular responses to Pneumocystis major surface glycoprotein variants in mice. BMC Immunology, 2012, 13, 39.	0.9	23
64	Influence of <i>Panax ginseng</i> on Cytochrome P450 (CYP)3A and Pâ€glycoprotein (Pâ€gp) Activity in Healthy Participants. Journal of Clinical Pharmacology, 2012, 52, 932-939.	1.0	103
65	HIV Infection and Antiretroviral Therapy Have Divergent Effects on Mitochondria in Adipose Tissue. Journal of Infectious Diseases, 2012, 205, 1778-1787.	1.9	45
66	LIPS arrays for simultaneous detection of antibodies against partial and whole proteomes of HCV, HIV and EBV. Molecular BioSystems, 2011, 7, 1453.	2.9	28
67	Nucleic Acid Amplification Tests for Diagnosis of Smear-Negative TB in a High HIV-Prevalence Setting: A Prospective Cohort Study. PLoS ONE, 2011, 6, e16321.	1.1	30
68	The Effect of Intermittent IL-2 Therapy on CD4 T Cells in the Gut in HIV-1–Infected Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 56, 340-343.	0.9	6
69	Partial immune reconstitution of X-linked hyper IgM syndrome with recombinant CD40 ligand. Blood, 2011, 118, 3811-3817.	0.6	39
70	Differential effects of HIV viral load and CD4 count on proliferation of naive and memory CD4 and CD8 T lymphocytes. Blood, 2011, 118, 262-270.	0.6	40
71	Galleria mellonella are Resistant to Pneumocystis murina Infection. Mycopathologia, 2011, 171, 273-277.	1.3	7
72	HIV-Associated Pneumocystis Pneumonia. Proceedings of the American Thoracic Society, 2011, 8, 294-300.	3.5	146

#	Article	IF	Citations
73	Lack of Compartmentalization of HIV-1 Quasispecies Between the Gut and Peripheral Blood Compartments. Journal of Infectious Diseases, 2011, 204, 309-314.	1.9	49
74	CD4 ⁺ T Cells, Including Th17 and Cycling Subsets, Are Intact in the Gut Mucosa of HIV-1-Infected Long-Term Nonprogressors. Journal of Virology, 2011, 85, 5880-5888.	1.5	80
75	<i>Echinacea purpurea</i> Significantly Induces Cytochrome P450 3A Activity but Does Not Alter Lopinavirâ€Ritonavir Exposure in Healthy Subjects. Pharmacotherapy, 2010, 30, 797-805.	1.2	51
76	HCV in peripheral blood mononuclear cells are predominantly carried on the surface of cells in HIV/HCV coâ€infected individuals. Journal of Medical Virology, 2010, 82, 2032-2037.	2.5	21
77	Distinct Profiles of Antibodies to Kaposi Sarcoma–Associated Herpesvirus Antigens in Patients with Kaposi Sarcoma, Multicentric Castleman Disease, and Primary Effusion Lymphoma. Journal of Infectious Diseases, 2010, 201, 1919-1922.	1.9	38
78	Characterization of the Meiosisâ€Specific Recombinase Dmc1 of <i>Pneumocystis</i> Infectious Diseases, 2010, 202, 1920-1929.	1.9	13
79	Proteomeâ€Wide Anti–Hepatitis C Virus (HCV) and Antiâ€HIV Antibody Profiling for Predicting and Monitoring the Response to HCV Therapy in HIVâ€Coinfected Patients. Journal of Infectious Diseases, 2010, 202, 894-898.	1.9	18
80	Interferon-α Produces Significant Decreases in HIV Load. Journal of Interferon and Cytokine Research, 2010, 30, 461-464.	0.5	37
81	Cycling of gut mucosal CD4+ T cells decreases after prolonged anti-retroviral therapy and is associated with plasma LPS levels. Mucosal Immunology, 2010, 3, 172-181.	2.7	71
82	Four-Antigen Mixture Containing V-Cyclin for Serological Screening of Human Herpesvirus 8 Infection. Vaccine Journal, 2009, 16, 621-627.	3.2	34
83	Evolving Health Effects of Pneumocystis. JAMA - Journal of the American Medical Association, 2009, 301, 2578.	3.8	160
84	Inferiority of IL-2 alone versus IL-2 with HAART in maintaining CD4 T cell counts during HAART interruption: a randomized controlled trial. Aids, 2009, 23, 203-212.	1.0	13
85	Polymerase Chain Reaction of <i>secA1</i> on Sputum or Oral Wash Samples for the Diagnosis of Pulmonary Tuberculosis. Clinical Infectious Diseases, 2009, 48, 725-732.	2.9	24
86	Restriction Fragment Length Polymorphism Typing Demonstrates Substantial Diversity among Pneumocystis jiroveciilsolates. Journal of Infectious Diseases, 2009, 200, 1616-1622.	1.9	28
87	High Sensitivity and Specificity of Acid-Fast Microscopy for Diagnosis of Pulmonary Tuberculosis in an African Population with a High Prevalence of Human Immunodeficiency Virus. Journal of Clinical Microbiology, 2009, 47, 1553-1555.	1.8	24
88	Gemfibrozil Concentrations Are Significantly Decreased in the Presence of Lopinavir-Ritonavir. Journal of Acquired Immune Deficiency Syndromes (1999), 2009, 52, 235-239.	0.9	24
89	Interleukin-2 cycling causes transient increases in high-sensitivity C-reactive protein and D-dimer that are not associated with plasma HIV-RNA levels. Aids, 2009, 23, 2015-2019.	1.0	17
90	Drug Resistance in Pneumocystis jirovecii. , 2009, , 993-1007.		0

#	Article	IF	Citations
91	Characterization of the expression site of the major surface glycoprotein of human-derived Pneumocystis carinii. Molecular Microbiology, 2008, 42, 183-193.	1.2	49
92	HIV related opportunistic infections: still relevant after 25 years of AIDS progress. Enfermedades Infecciosas Y MicrobiologÃa CIÃnica, 2008, 26, 323-324.	0.3	4
93	Idiopathic CD4+ Lymphocytopenia: Natural History and Prognostic Factors International Journal of Infectious Diseases, 2008, 12, S7.	1.5	0
94	The Effect of Continuous Versus Pericycle Antiretroviral Therapy on IL-2 Responsiveness. Journal of Interferon and Cytokine Research, 2008, 28, 455-462.	0.5	1
95	Persistence of HIV in Gutâ€Associated Lymphoid Tissue despite Longâ€Term Antiretroviral Therapy. Journal of Infectious Diseases, 2008, 197, 714-720.	1.9	489
96	<i>Pneumocystis</i> Encodes a Functional <i>S</i> Adenosylmethionine Synthetase Gene. Eukaryotic Cell, 2008, 7, 258-267.	3 . 4	16
97	Immune responses to <i>Pneumocystis murina</i> li>are robust in healthy mice but largely absent in CD40 ligand-deficient mice. Journal of Leukocyte Biology, 2008, 84, 420-430.	1.5	35
98	Variation in the Major Surface Glycoprotein Genes in <i>Pneumocystis jirovecii </i> Infectious Diseases, 2008, 198, 741-749.	1.9	47
99	CD4 T Cell Survival after Intermittent Interleukinâ€2 Therapy Is Predictive of an Increase in the CD4 T Cell Count of HIVâ€Infected Patients. Journal of Infectious Diseases, 2008, 198, 843-850.	1.9	18
100	Influence of Antiretroviral Drugs on the Pharmacokinetics of Prednisolone in HIV-Infected Individuals. Journal of Acquired Immune Deficiency Syndromes (1999), 2008, 48, 561-566.	0.9	18
101	Idiopathic CD4+ lymphocytopenia: natural history and prognostic factors. Blood, 2008, 112, 287-294.	0.6	243
102	Does atovaquone provide effective prophylaxis for Pneumocystis pneumonia in children with leukemia?. Nature Clinical Practice Oncology, 2007, 4, 566-567.	4.3	0
103	ART Suppresses Plasma HIV-1 RNA to a Stable Set Point Predicted by Pretherapy Viremia. PLoS Pathogens, 2007, 3, e46.	2.1	296
104	The Incidence and Natural History of Osteonecrosis in HIV-Infected Adults. Clinical Infectious Diseases, 2007, 44, 739-748.	2.9	108
105	CD4+T Cell Responses to Interleukinâ€⊋ Administration in HIVâ€Infected Patients Are Directly Related to the Baseline Level of Immune Activation. Journal of Infectious Diseases, 2007, 196, 677-683.	1.9	15
106	Rapid antibody quantification and generation of whole proteome antibody response profiles using LIPS (luciferase immunoprecipitation systems). Biochemical and Biophysical Research Communications, 2007, 352, 889-895.	1.0	63
107	Identification and characterization of rad51 of Pneumocystis. Gene, 2007, 389, 204-211.	1.0	3
108	Metabolic and Skeletal Complications of HIV Infection. JAMA - Journal of the American Medical Association, 2006, 296, 844.	3.8	98

#	Article	IF	CITATIONS
109	Lopinavirâ€Ritonavir: Effects on Endothelial Cell Function in Healthy Subjects. Journal of Infectious Diseases, 2006, 193, 1516-1519.	1.9	28
110	Nail ve T-Cell Dynamics in Human Immunodeficiency Virus Type 1 Infection: Effects of Highly Active Antiretroviral Therapy Provide Insights into the Mechanisms of Nail ve T-Cell Depletion. Journal of Virology, 2006, 80, 2665-2674.	1,5	66
111	Prednisolone Pharmacokinetics in the Presence and Absence of Ritonavir After Oral Prednisone Administration to Healthy Volunteers. Journal of Acquired Immune Deficiency Syndromes (1999), 2005, 40, 573-580.	0.9	41
112	Induction of prolonged survival of CD4+ T lymphocytes by intermittent IL-2 therapy in HIV-infected patients. Journal of Clinical Investigation, 2005, 115, 2139-2148.	3.9	115
113	In vivo expansion of CD4+CD45RO-CD25+ T cells expressing foxP3 in IL-2-treated HIV-infected patients. Journal of Clinical Investigation, 2005, 115, 1839-1847.	3.9	109
114	Strain Typing Methods and Molecular Epidemiology of <i>Pneumocystis </i> Infectious Diseases, 2004, 10, 1729-1735.	2.0	61
115	A Prospective, Blinded Study of Quantitative Touchâ€Down Polymerase Chain Reaction Using Oralâ€Wash Samples for Diagnosis ofPneumocystisPneumonia in HIVâ€Infected Patients. Journal of Infectious Diseases, 2004, 189, 1679-1683.	1.9	99
116	HIV Infection, Hepatitis C Infection, and HAART. JAMA - Journal of the American Medical Association, 2004, 292, 243.	3.8	23
117	Quantitative Realâ€Time Polymerase Chainâ€Reaction Assay Allows Characterization ofPneumocystisInfection in Immunocompetent Mice. Journal of Infectious Diseases, 2004, 189, 1540-1544.	1.9	45
118	Inability of Pneumocystis organisms to incorporate bromodeoxyuridine suggests the absence of a salvage pathway for thymidine. Microbiology (United Kingdom), 2004, 150, 1179-1182.	0.7	6
119	Plasma Pharmacokinetics of Sulfadiazine Administered Twice Daily versus Four Times Daily Are Similar in Human Immunodeficiency Virus-Infected Patients. Antimicrobial Agents and Chemotherapy, 2004, 48, 635-637.	1.4	14
120	Induction and maintenance therapy with intermittent interleukin-2 in HIV-1 infection. Blood, 2004, 103, 3282-3286.	0.6	47
121	IL-2–induced CD4+ T-cell expansion in HIV-infected patients is associated with long-term decreases in T-cell proliferation. Blood, 2004, 104, 775-780.	0.6	93
122	A Comparison of $^1\text{/4}LC$ /Electrospray Ionization-MS and GC/MS for the Measurement of Stable Isotope Enrichment from a [2H2]-Glucose Metabolic Probe in T-Cell Genomic DNA. Analytical Chemistry, 2003, 75, 6517-6522.	3.2	10
123	Characterization of thioredoxin reductase genes (trr1) from Pneumocystis carinii and Pneumocystis jiroveci. Gene, 2003, 310, 175-183.	1.0	9
124	A Randomized, Doubleâ€Blinded, Placeboâ€Controlled Trial of Intermittent Administration of Interleukinâ€2 and Prednisone in Subjects Infected with Human Immunodeficiency Virus. Journal of Infectious Diseases, 2003, 188, 531-536.	1.9	13
125	Quantitation of Anti–Pneumocystis jiroveciAntibodies in Healthy Persons and Immunocompromised Patients. Journal of Infectious Diseases, 2003, 187, 1844-1848.	1.9	50
126	Characterization of variants of the gene encoding the p55 antigen in Pneumocystis from rats and mice. Journal of Medical Microbiology, 2003, 52, 955-960.	0.7	17

#	Article	IF	CITATIONS
127	Surrogate Markers of Immune Function in Human Immunodeficiency Virus–Infected Patients: What Are They Surrogates For?. Journal of Infectious Diseases, 2003, 188, 1791-1793.	1.9	7
128	A Single-Copy Gene Encodes Kex1, a Serine Endoprotease of Pneumocystis jiroveci. Infection and Immunity, 2003, 71, 571-574.	1.0	39
129	Increases in CD4+ T Lymphocytes Occur Without Increases in Thymic Size in HIV-Infected Subjects Receiving Interleukin-2 Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2003, 34, 299-303.	0.9	10
130	Suppression of cerebrospinal fluid HIV burden in antiretroviral naive patients on a potent four-drug antiretroviral regimen. Aids, 2003, 17, 1167-1172.	1.0	30
131	Development of a Rapid Real-Time PCR Assay for Quantitation of Pneumocystis carinii f. sp. carinii. Journal of Clinical Microbiology, 2002, 40, 2989-2993.	1.8	53
132	Increased peripheral expansion of naive CD4+ T cells in vivo after IL-2 treatment of patients with HIV infection. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 10712-10717.	3.3	65
133	Mutations in the Dihydropteroate Synthase Gene of Humanâ€DerivedPneumocystis cariniilsolates from Italy Are Infrequent but Correlate with Prior Sulfa Prophylaxis. Journal of Infectious Diseases, 2002, 185, 1530-1532.	1.9	57
134	Development of a Yeast Assay for Rapid Screening of Inhibitors of Human-Derived Pneumocystis carinii Dihydrofolate Reductase. Antimicrobial Agents and Chemotherapy, 2002, 46, 3101-3103.	1.4	10
135	Analysis of Variation in Tandem Repeats in the Intron of the Major Surface Glycoprotein Expression Site of the Human Form ofPneumocystis carinii. Journal of Infectious Diseases, 2002, 186, 1647-1654.	1.9	37
136	Development and Evaluation of a Quantitative, Touch-Down, Real-Time PCR Assay for Diagnosing Pneumocystis carinii Pneumonia. Journal of Clinical Microbiology, 2002, 40, 490-494.	1.8	154
137	High Prevalence of Osteonecrosis of the Femoral Head in HIV-Infected Adults. Annals of Internal Medicine, 2002, 137, 17.	2.0	153
138	Diagnosis of avascular necrosis of the hip in asymptomatic HIV-infected patients: Clinical correlation of physical examination with magnetic resonance imaging. Journal of Back and Musculoskeletal Rehabilitation, 2002, 16, 135-139.	0.4	8
139	Long-term effects of intermittent interleukin 2 therapy in patients with HIV infection: characterization of a novel subset of CD4+/CD25+ T cells. Blood, 2002, 100, 2159-2167.	0.6	69
140	Long-term effects of intermittent interleukin 2 therapy in patients with HIV infection: characterization of a novel subset of CD4+/CD25+ T cells. Blood, 2002, 100, 2159-2167.	0.6	2
141	Long-term effects of intermittent interleukin 2 therapy in patients with HIV infection: characterization of a novel subset of CD4(+)/CD25(+) T cells. Blood, 2002, 100, 2159-67.	0.6	19
142	Immunotherapy of HIV-Infected Patients with Intermittent Interleukin-2: Effects of Cycle Frequency and Cycle Duration on Degree of CD4+ T-Lymphocyte Expansion. Clinical Immunology, 2001, 99, 30-42.	1.4	20
143	CD4 T cell expansions are associated with increased apoptosis rates of T lymphocytes during IL-2 cycles in HIV infected patients. Aids, 2001, 15, 1765-1775.	1.0	50
144	Interleukin-2 induced immune effects in human immunodeficiency virus-infected patients receiving intermittent interleukin-2 immunotherapy. European Journal of Immunology, 2001, 31, 1351-1360.	1.6	56

#	Article	IF	Citations
145	Recombinant CD40 Ligand Administration Does Not Decrease Intensity of Pneumocystis carinii Infection in Scid Mice. Journal of Eukaryotic Microbiology, 2001, 48, 153s-154s.	0.8	1
146	Genetic Analysis of Multiple Loci Suggests that Mutations in the Pneumocystis carinii f. sp. hominis Dihydropteroate Synthase Gene Arose Independently in Multiple Strains. Antimicrobial Agents and Chemotherapy, 2001, 45, 3213-3215.	1.4	28
147	The Use of Oral Washes to DiagnosePneumocystis cariniiPneumonia: A Blinded Prospective Study Using a Polymerase Chain Reaction–Based Detection System. Journal of Infectious Diseases, 2001, 184, 1485-1488.	1.9	59
148	New Insights Into Transmission, Diagnosis, and Drug Treatment of <emph type="ITAL">Pneumocystis carinii</emph> Pneumonia. JAMA - Journal of the American Medical Association, 2001, 286, 2450.	3.8	191
149	Rapid Detection of Mutations in the Human-Derived Pneumocystis carinii Dihydropteroate Synthase Gene Associated with Sulfa Resistance. Antimicrobial Agents and Chemotherapy, 2001, 45, 776-780.	1.4	20
150	Identification of Dynamically Distinct Subpopulations of T Lymphocytes That Are Differentially Affected by HIV. Journal of Experimental Medicine, 2001, 194, 1731-1741.	4.2	203
151	Genetic Divergence of the Dihydrofolate Reductase and Dihydropteroate Synthase Genes inPneumocystis cariniifrom 7 Different Host Species. Journal of Infectious Diseases, 2001, 184, 1358-1362.	1.9	41
152	Lactic Acidosis and Hepatic Steatosis Associated with Use of Stavudine: Report of Four Cases. Annals of Internal Medicine, 2000, 133, 192.	2.0	184
153	Impact of HIV-1 infection and highly active antiretroviral therapy on the kinetics of CD4+ and CD8+ T cell turnover in HIV-infected patients. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 13778-13783.	3.3	175
154	Immunization with a DNA Plasmid Encoding the SAG1 (P30) Protein of Toxoplasma gondiils Immunogenic and Protective in Rodents. Journal of Infectious Diseases, 2000, 181, 317-324.	1.9	137
155	Rapid activation of lymph nodes and mononuclear cell HIV expression upon interrupting highly active antiretroviral therapy in patients after prolonged viral suppression. Aids, 2000, 14, 1709-1715.	1.0	38
156	Pooled Analysis of 3 Randomized, Controlled Trials of Interleukinâ€⊋ Therapy in Adult Human Immunodeficiency Virus Type 1 Disease. Journal of Infectious Diseases, 2000, 182, 428-434.	1.9	105
157	Prophylaxis against Opportunistic Infections in Patients with Human Immunodeficiency Virus Infection. New England Journal of Medicine, 2000, 342, 1416-1429.	13.9	221
158	Interleukinâ€2 Upâ€Regulates Expression of the Human Immunodeficiency Virus Fusion Coreceptor CCR5 by CD4+Lymphocytes In Vivo. Journal of Infectious Diseases, 2000, 181, 933-938.	1.9	46
159	Effects of Intermittent Interleukinâ€2 Therapy on Plasma and Tissue Human Immunodeficiency Virus Levels and Quasiâ€5pecies Expression. Journal of Infectious Diseases, 2000, 182, 1063-1069.	1.9	31
160	Expression and Characterization of Recombinant Human-Derived Pneumocystis carinii Dihydrofolate Reductase. Antimicrobial Agents and Chemotherapy, 2000, 44, 3092-3096.	1.4	30
161	Discontinuation of Anticytomegalovirus Therapy in Patients With HIV Infection and Cytomegalovirus Retinitis. JAMA - Journal of the American Medical Association, 1999, 282, 1633.	3.8	163
162	Identification and Characterization of Novel Variant Major Surface Glycoprotein Gene Families in RatPneumocystis carinii. Journal of Infectious Diseases, 1999, 179, 192-200.	1.9	94

#	Article	IF	Citations
163	A Randomized Trial of High†versus Lowâ€Dose Subcutaneous Interleukinâ€2 Outpatient Therapy for Early Human Immunodeficiency Virus Type 1 Infection. Journal of Infectious Diseases, 1999, 179, 849-858.	1.9	149
164	Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. Nature Medicine, 1999, 5, 651-655.	15.2	400
165	Atovaquone Suspension in HIV-Infected Volunteers: Pharmacokinetics, Pharmacodynamics, and TMP-SMX Interaction Study. Pharmacotherapy, 1999, 19, 1050-1056.	1.2	41
166	Development of a PCR assay for diagnosis of Pneumocystis carinii pneumonia based on amplification of the multicopy major surface glycoprotein gene family. Diagnostic Microbiology and Infectious Disease, 1999, 35, 27-32.	0.8	40
167	HIV-1 replication in patients with undetectable plasma virus receiving HAART. Lancet, The, 1999, 353, 119-120.	6.3	142
168	Pneumocystis cariniiDihydropteroate Synthase but Not Dihydrofolate Reductase Gene Mutations Correlate with Prior Trimethoprimâ€Sulfamethoxazole or Dapsone Use. Journal of Infectious Diseases, 1999, 180, 1969-1978.	1.9	163
169	HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 15109-15114.	3.3	751
170	Lymph node architecture preceding and following 6 months of potent antiviral therapy: follicular hyperplasia persists in parallel with p24 antigen Restoration after involution and CD4 cell depletion in an AIDS patient. Aids, 1999, 13, 2219-2229.	1.0	65
171	Characterization of a Multicopy Family of Genes Encoding a Surface-Expressed Serine Endoprotease in Rat Pneumocystis carinii. Proceedings of the Association of American Physicians, 1999, 111, 347-356.	2.1	25
172	Pharmacokinetic modeling of recombinant interleukin-2 in patients with human immunodeficiency virus infection. Clinical Pharmacology and Therapeutics, 1998, 64, 492-498.	2.3	16
173	Peripheral expansion of pre-existing mature T cells is an important means of CD4+ T-cell regeneration HIV-infected adults. Nature Medicine, 1998, 4, 852-856.	15.2	115
174	Failure of co-trimoxazole in Pneumocystis carinii infection and mutations in dihydropteroate synthase gene. Lancet, The, 1998, 351, 1631-1632.	6.3	99
175	Pneumocystis carinii: a fungus resistant to antifungal therapies $\hat{a} \in \mathbb{C}$ mechanisms of action of antipneumocystis drugs. Drug Resistance Updates, 1998, 1, 16-20.	6.5	4
176	Prospective sonographic evaluation of interleukin-2-induced changes in the gallbladder Radiology, 1998, 206, 393-396.	3.6	10
177	Characterization of Major Surface Glycoprotein Genes of Human <i>Pneumocystis carinii</i> High-Level Expression of a Conserved Region. Infection and Immunity, 1998, 66, 4268-4273.	1.0	51
178	Characterization of Major Surface Glycoprotein Genes of Human Pneumocystis carinii and High-Level Expression of a Conserved Region. Infection and Immunity, 1998, 66, 4268-4273.	1.0	8
179	Clarithromycin lowers plasma zidovudine levels in persons with human immunodeficiency virus infection. Antimicrobial Agents and Chemotherapy, 1997, 41, 1709-1714.	1.4	41
180	HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nature Medicine, 1997, 3, 533-540.	15.2	501

#	Article	IF	CITATIONS
181	Randomized, controlled phase I/II, trial of combination therapy with delavirdine (U-90152S) and conventional nucleosides in human immunodeficiency virus type 1-infected patients. Antimicrobial Agents and Chemotherapy, 1996, 40, 1657-1664.	1.4	71
182	Effects of cytokines on antiviral pharmacokinetics: an alternative approach to assessment of drug interactions using bioequivalence guidelines. Antimicrobial Agents and Chemotherapy, 1996, 40, 161-165.	1.4	16
183	The Laboratory Evaluation of Opportunistic Pulmonary Infections. Annals of Internal Medicine, 1996, 124, 585.	2.0	73
184	Expression of the Major Surface Glycoprotein of Rat-derived Pneumocystis carinii by Recombinant Baculovirus. Journal of Eukaryotic Microbiology, 1996, 43, 31S-31S.	0.8	6
185	Nucleic Acid Vaccination against Toxoplasma gondii in Mice. Journal of Eukaryotic Microbiology, 1996, 43, 117S-117S.	0.8	17
186	Combination Therapy with Didanosine and Interferon-a in Human Immunodeficiency Virus-Infected Patients: Results of a Phase I/II Trial. Journal of Infectious Diseases, 1996, 173, 840-848.	1.9	29
187	Inhibition of Immunoreactive Tumor Necrosis Factor-Â by a Chimeric Antibody in Patients Infected with Human Immunodeficiency Virus Type 1. Journal of Infectious Diseases, 1996, 174, 63-68.	1.9	71
188	Expression of variants of the major surface glycoprotein of Pneumocystis carinii Journal of Experimental Medicine, 1996, 183, 1229-1234.	4.2	57
189	A Single Expression Site with a Conserved Leader Sequence Regulates Variation of Expression of the <i>> Pneumocystis carinii < /i> Family of Major Surface Glycoprotein Genes. DNA and Cell Biology, 1996, 15, 989-999.</i>	0.9	62
190	Controlled Trial of Interleukin-2 Infusions in Patients Infected with the Human Immunodeficiency Virus. New England Journal of Medicine, 1996, 335, 1350-1356.	13.9	429
191	Efficacy of Epiroprim (Ro11-8958), a New Dihydrofolate Reductase Inhibitor, in the Treatment of Acute Toxoplasma Infection in Mice. American Journal of Tropical Medicine and Hygiene, 1996, 54, 249-252.	0.6	13
192	Anticytomegaloviral activity and safety of cidofovir in patients with human immunodeficiency virus infection and cytomegalovirus viruria. Antimicrobial Agents and Chemotherapy, 1995, 39, 882-886.	1.4	142
193	Toxoplasmosis in AIDS: Keeping the Lid On. Annals of Internal Medicine, 1995, 123, 230.	2.0	7
194	Increases in CD4 T Lymphocytes with Intermittent Courses of Interleukin-2 in Patients with Human Immunodeficiency Virus Infection — A Preliminary Study. New England Journal of Medicine, 1995, 332, 567-575.	13.9	433
195	Preventing Toxoplasmic Encephalitis in Persons Infected with Human Immunodeficiency Virus. Clinical Infectious Diseases, 1995, 21, S49-S56.	2.9	57
196	Pneumocystis carinii in Africa: an emerging pathogen?. Lancet, The, 1995, 346, 1242-1243.	6.3	25
197	Pharmacokinetics and safety of weekly dapsone and dapsone plus pyrimethamine for prevention of pneumocystis pneumonia. Antimicrobial Agents and Chemotherapy, 1994, 38, 1580-1587.	1.4	20
198	Interaction of Pneumocystis carinii Dihydropteroate Synthase with Sulfonamides and Diaminodiphenyl Sulfone (Dapsone). Journal of Infectious Diseases, 1994, 169, 456-459.	1.9	29

#	Article	IF	Citations
199	Symptomatic interleukin-2-induced cholecystopathy in patients with HIV infection American Journal of Roentgenology, 1994, 163, 117-121.	1.0	11
200	Application OF Branched DNA Signal Amplification to Monitor Human Immunodeficiency Virus Type 1 Burden in Human Plasma. Journal of Infectious Diseases, 1994, 170, 1172-1179.	1.9	190
201	PCP prophylaxis in paediatric HIV infection: time for a change?. Lancet, The, 1994, 344, 5-6.	6.3	12
202	Use Of Recombinant Soluble Cd4 Pseudomonas Exotoxin, A Novel Immunotoxin, For Treatment Of Persons Infected With Human Immunodeficiency Virus. Journal of Infectious Diseases, 1994, 170, 1180-1188.	1.9	54
203	The Challenge of Pneumocystis carinii Culture. Journal of Eukaryotic Microbiology, 1993, 40, 188-195.	0.8	91
204	Increased survival of a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis who received sodium phosphonoformate (Foscarnet). American Journal of Medicine, 1993, 94, 175-180.	0.6	49
205	Inhibition of Pneumocystis carinii dihydropteroate synthetase by para-acetamidobenzoic acid: possible mechanism of action of isoprinosine in human immunodeficiency virus infection. Antimicrobial Agents and Chemotherapy, 1993, 37, 1227-1231.	1.4	7
206	IgM Response to a Human Pneumocystis carinii Surface Antigen in HIV-infected Patients with Pulmonary Symptoms. Scandinavian Journal of Infectious Diseases, 1993, 25, 515-520.	1.5	17
207	Salvage Trial of Trimetrexate-Leucovorin for the Treatment of Cerebral Toxoplasmosis in Patients with AIDS. Journal of Infectious Diseases, 1993, 167, 1422-1426.	1.9	43
208	Development and characterization of a rapid screening assay for identifying antipneumocystis agents. Antimicrobial Agents and Chemotherapy, 1993, 37, 1674-1678.	1.4	11
209	Leukotriene B4 and Interleukin-8 in Human Immunodeficiency Virus-related Pulmonary Disease. Chest, 1993, 104, 763-769.	0.4	55
210	Plasma viremia as a sensitive indicator of the antiretroviral activity of L-697,661 Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 5608-5612.	3.3	48
211	Induction of humoral and cell-mediated anti-human immunodeficiency virus (HIV) responses in HIV sero-negative volunteers by immunization with recombinant gp160 Journal of Clinical Investigation, 1993, 92, 919-928.	3.9	43
212	Antibody Responses to a Major Pneumocystis carinii Antigen in Human Immunodeficiency Virus-Infected Patients with and without P. carinii Pneumonia. Journal of Infectious Diseases, 1992, 165, 1151-1155.	1.9	47
213	Prophylaxis for Pneumocystis carinii Pneumonia in Patients Infected with Human Immunodeficiency Virus. Clinical Infectious Diseases, 1992, 14, 1005-1009.	2.9	35
214	Reduction of Pulmonary Surfactant in Patients with Human Immunodeficiency Virus Infection and Pneumocystis carinii Pneumonia. Chest, 1992, 102, 1730-1736.	0.4	70
215	Improved diagnosis of Pneumocystis carinii infection by polymerase chain reaction on induced sputum and blood. Lancet, The, 1992, 340, 203-206.	6.3	181
216	Efficacy of atovaquone in treatment of toxoplasmosis in patients with AIDS. Lancet, The, 1992, 340, 637-638.	6.3	137

#	Article	IF	Citations
217	Phase I/II Studies of the Toxicity and Immunogenicity of Recombinant gp160 and p24 Vaccines in HIV-Infected Individuals. AIDS Research and Human Retroviruses, 1992, 8, 1335-1335.	0.5	6
218	Indeterminate western blot patterns in a cohort of individuals at high risk for human immunodeficiency virus (HIV-1) exposure. Journal of Clinical Immunology, 1992, 12, 185-192.	2.0	16
219	Chemotherapeutic Targets in Pneumocystis carinii. , 1992, , 568-588.		1
220	Pneumocystis carinii and specific fungi have a common epitope, identified by a monoclonal antibody. Journal of Clinical Microbiology, 1992, 30, 391-395.	1.8	23
221	A Randomized, Controlled Trial of Foscarnet in the Treatment of Cytomegalovirus Retinitis in Patients with AIDS. Annals of Internal Medicine, 1991, 115, 665-673.	2.0	309
222	A Phase I/II Trial of Zidovudine, Interferon-Â, and Granulocyte-Macrophage Colony-Stimulating Factor in the Treatment of Human Immunodeficiency Virus Type 1 Infection. Journal of Infectious Diseases, 1991, 164, 43-52.	1.9	60
223	A Preliminary Evaluation of 566C80 for the Treatment of Pneumocystis Pneumonia in Patients with the Acquired Immunodeficiency Syndrome. New England Journal of Medicine, 1991, 325, 1534-1538.	13.9	82
224	Polyamine Metabolism in Pneumocystis carinii. Journal of Infectious Diseases, 1991, 163, 1121-1127.	1.9	16
225	Purification and characterization of a major human Pneumocystis carinii surface antigen Journal of Clinical Investigation, 1991, 87, 163-170.	3.9	105
226	Immunoperoxidase Localization of Pneumocystis cariniiin Formalin Fixed, Paraffin Embedded Tissue with Monoclonal Antibody 2G2. Journal of Histotechnology, 1990, 13, 117-120.	0.2	3
227	Atypical Pathologic Manifestations of Pneumocystis carinii Pneumonia in the Acquired Immune Deficiency Syndrome. American Journal of Surgical Pathology, 1990, 14, 615-625.	2.1	146
228	Syngeneic Bone Marrow Transplantation and Adoptive Transfer of Peripheral Blood Lymphocytes Combined with Zidovudine in Human Immunodeficiency Virus (HIV) Infection. Annals of Internal Medicine, 1990, 113, 512.	2.0	65
229	Are Corticosteroids Beneficial as Adjunctive Therapy for Pneumocystis Pneumonia in AIDS?. Annals of Internal Medicine, 1990, 113, 1.	2.0	28
230	Effects of interferon- \hat{l}_{\pm} in patients with aids-associated Kaposi's sarcoma are related to blood interferon levels and dose. Cytokine, 1990, 2, 247-252.	1.4	16
231	Characterization of dihydrofolate reductase of Pneumocystis carinii and Toxoplasma gondii. Experimental Parasitology, 1990, 71, 60-68.	0.5	27
232	Interaction of sulfonamide and sulfone compounds with Toxoplasma gondii dihydropteroate synthase Journal of Clinical Investigation, 1990, 85, 371-379.	3.9	53
233	Interferon- \hat{l}_{\pm} in Patients with Asymptomatic Human Immunodeficiency Virus (HIV) Infection. Annals of Internal Medicine, 1990, 112, 805.	2.0	212
234	Characterization of De Novo Folate Synthesis in Pneumocystis cannu and Toxoplasma gondii: Potential for Screening Therapeutic Agents. Journal of Infectious Diseases, 1989, 160, 312-320.	1.9	98

#	Article	IF	CITATIONS
235	Monoclonal Antibodies to Pneumocystis carinii: Identification of Specific Antigens and Characterization of Antigenic Differences Between Rat and Human Isolates. Journal of Infectious Diseases, 1989, 159, 60-70.	1.9	144
236	The Cardiovascular Response of Normal Humans to the Administration of Endotoxin. New England Journal of Medicine, 1989, 321, 280-287.	13.9	1,107
237	Reversible Cardiac Dysfunction Associated with Interferon Alfa Therapy in AIDS Patients with Kaposi's Sarcoma. New England Journal of Medicine, 1989, 321, 1246-1249.	13.9	123
238	Prophylaxis of Pneumocystis carinii Pneumonia: An Update. Journal of Infectious Diseases, 1989, 160, 882-886.	1.9	45
239	Identification of Antigens Specific for <i>Pneumocystis carinii</i> . Journal of Protozoology, 1989, 36, 67S-69S.	0.9	7
240	Ribosomal RNA Genes of Pneumocystis carinii. Journal of Protozoology, 1989, 36, 18s-20s.	0.9	7
241	Identification of Antigens Specific forPneumocystis carinii. Journal of Protozoology, 1989, 36, 67s-69s.	0.9	3
242	Induced sputum to diagnose Pneumocystis carinii pneumonia in immunosuppressed pediatric patients. Journal of Pediatrics, 1989, 115, 430-433.	0.9	46
243	Ribosomal RNA Genes of Pneumocystis carinii. Journal of Protozoology, 1989, 36, 18S-20S.	0.9	24
244	Isolation and expression of the Pneumocystis carinii dihydrofolate reductase gene Proceedings of the National Academy of Sciences of the United States of America, 1989, 86, 8625-8629.	3.3	155
245	CD4 Counts as Predictors of Opportunistic Pneumonias in Human Immunodeficiency Virus (HIV) Infection. Annals of Internal Medicine, 1989, 111, 223.	2.0	458
246	Zidovudine in Patients with Human Immunodeficiency Virus (HIV) Infection and Kaposi Sarcoma. Annals of Internal Medicine, 1989, 111, 41.	2.0	85
247	Pneumocystis Pneumonia: From Bench to Clinic. Annals of Internal Medicine, 1989, 111, 813.	2.0	107
248	Combined Zidovudine and Interferon-α Therapy in Patients with Kaposi Sarcoma and the Acquired Immunodeficiency Syndrome (AIDS). Annals of Internal Medicine, 1989, 111, 280.	2.0	187
249	Ribosomal RNA sequence shows Pneumocystis carinii to be a member of the Fungi. Nature, 1988, 334, 519-522.	13.7	812
250	Disseminated mycobacterium haemophilum infection in two patients with the acquired immunodeficiency syndrome. American Journal of Medicine, 1988, 84, 640-642.	0.6	94
251	ANTI-RETROVIRAL EFFECTS OF INTERFERON-α IN AIDS-ASSOCIATED KAPOSI'S SARCOMA. Lancet, The, 1988, 332 1218-1222.	., 6.3	246
252	Pneumocystis carinii Pneumonia: Therapy and Prophylaxis. Journal of Infectious Diseases, 1988, 158, 254-259.	1.9	138

#	Article	IF	Citations
253	Potent antipneumocystis and antitoxoplasma activities of piritrexim, a lipid-soluble antifolate. Antimicrobial Agents and Chemotherapy, 1988, 32, 430-433.	1.4	98
254	DIAGNOSIS OF PNEUMOCYSTIS CARINII PNEUMONIA (PCP) BY IMMUNOFLUORESCENT (IF) STAINING OF INDUCED SPUTUM. Critical Care Medicine, 1988, 16, 399.	0.4	0
255	Anemia and Erythropoiesis in Patients with the Acquired Immunodeficiency Syndrome (AIDS) and Kaposi Sarcoma Treated with Zidovudine. Annals of Internal Medicine, 1988, 108, 372.	2.0	92
256	Diagnosis of <i>Pneumocystis carinii </i> Pneumonia: Improved Detection in Sputum with Use of Monoclonal Antibodies. New England Journal of Medicine, 1988, 318, 589-593.	13.9	352
257	CIRCULATING TUMOR NECROSIS FACTOR IN NORMAL VOLUNTEERS RECEIVING ENDOTOXIN. Critical Care Medicine, 1988, 16, 397.	0.4	10
258	Diagnosis of Pneumocystis Pneumonia by Induced Sputum Technique in Patients without the Acquired Immunodeficiency Syndrome. Annals of Internal Medicine, 1988, 109, 755.	2.0	30
259	Treatment and Prophylaxis of Pneumocystis carinii Pneumonia. Infectious Disease Clinics of North America, 1988, 2, 419-428.	1.9	11
260	Efficacy of Trimetrexate, a Potent Lipid-Soluble Antifolate, in the Treatment of Rodent Pneumocystis Carinii Pneumonia. American Journal of Tropical Medicine and Hygiene, 1988, 39, 491-496.	0.6	23
261	Trimetrexate for the Treatment of <i>Pneumocystis carinii </i> Immunodeficiency Syndrome. New England Journal of Medicine, 1987, 317, 978-985.	13.9	243
262	Potent Effect of Trimetrexate, a Lipid-Soluble Antifolate, on Toxoplasma gondii. Journal of Infectious Diseases, 1987, 155, 1027-1032.	1.9	55
263	Developmental Therapeutics and the Acquired Immunodeficiency Syndrome. Annals of Internal Medicine, 1987, 106, 568.	2.0	95
264	Detection of Pneumocystis carinii by fluorescent-antibody stain using a combination of three monoclonal antibodies. Journal of Clinical Microbiology, 1987, 25, 1837-1840.	1.8	84
265	Potent in vitro and in vivo antitoxoplasma activity of the lipid-soluble antifolate trimetrexate Journal of Clinical Investigation, 1987, 79, 478-482.	3.9	70
266	PROSPECTIVE EVALUATION OF A MONOCLONAL ANTIBODY IN DIAGNOSIS OF PNEUMOCYSTIS CARINII PNEUMONIA. Lancet, The, 1986, 328, 1-3.	6.3	142
267	Protozoan Infections of Man: Other Infections. , 1986, , 139-158.		3
268	Cryptococcosis in the Acquired Immunodeficiency Syndrome. Annals of Internal Medicine, 1985, 103, 533.	2.0	620
269	INFECTIONS DUE TO PNEUMOCYSTIS CARINII AND MYCOBACTERIUM AVIUM-INTRACELLULARE IN PATIENTS WITH ACQUIRED IMMUNE DEFICIENCY SYNDROME. Annals of the New York Academy of Sciences, 1984, 437, 394-399.	1.8	6
270	Pneumocystis carinii Pneumonia: A Comparison Between Patients with the Acquired Immunodeficiency Syndrome and Patients with Other Immunodeficiencies. Annals of Internal Medicine, 1984, 100, 663.	2.0	794

#	Article	IF	CITATIONS
271	Persistence of Pneumocystis carinii in lung tissue of acquired immunodeficiency syndrome patients treated for pneumocystis pneumonia. The American Review of Respiratory Disease, 1984, 130, 1161-5.	2.9	82
272	Bacteremia Due to Mycobacterium avium-intracellulare in the Acquired Immunodeficiency Syndrome. Annals of Internal Medicine, 1983, 99, 782.	2.0	182